Rate My Professor Eddy Kizana

Kizana's academic interests lie in cardiac gene therapy, specializing in adeno-associated virus (AAV) vector development and their use in preclinical models of human heart conditions, including tachyarrhythmias, genetic cardiomyopathies, and post-infarct remodeling. This highly collaborative research aims to create next-generation vectors to enable effective human cardiac gene therapy. He has received prestigious funding, such as NHMRC Ideas Grants: $1,603,928.40 in 2024 for 'Creation of Next Generation Vectors for Cardiac Gene Therapy'; $1,558,213.50 in 2026 for 'Definitive and Personalised Therapy for Genetic Heart Disease'; and an earlier NHMRC Ideas Grant in 2019. Other awards include a Medical Research Future Fund grant in 2023 and the ALCC Award in 2015. Key publications include 'Adeno-associated virus–mediated gene therapy for cardiac tachyarrhythmia: A systematic review and meta-analysis' (Heart Rhythm, 2024); 'Development of new adeno-associated virus capsid variants for targeted gene delivery to human cardiomyocytes' (Molecular Therapy - Methods & Clinical Development, 2023); 'Gene therapy in cardiology: is a cure for hypertrophic cardiomyopathy on the horizon?' (Canadian Journal of Cardiology, 2024); 'Potential Applications for Targeted Gene Therapy to Protect Against Anthracycline Cardiotoxicity' (JACC: CardioOncology, 2021); and 'Recombinant Adeno-Associated Viral Vector-Mediated Gene Transfer of hTBX18 Generates Pacemaker Cells from Ventricular Cardiomyocytes'. Kizana mentors PhD and Honours students and contributes to advancements in cardiovascular precision medicine.